The session reviews the mechanisms, clinical evidence, and practical use of ultra-long acting therapies transforming metabolic disease management. It covers weekly basal insulin icodec, the first monthly GLP-1RA maridebart cafraglutide, and twice-yearly siRNA-based LDL-lowering therapy with inclisiran.
Experts will discuss how these agents simplify care and improve cardiometabolic outcomes.
The session aims to provide practical guidance for clinical application.

This symposium will address new strategies to enhance the efficacy of GLP-1 receptor agonists and overcome their limitations. Prof. Stephan Jacob will present clinical insights on retatrutide, a triple GLP-1/GIP/glucagon receptor agonist; Prof. Jang Won Son will discuss econoglutide, a biased GLP-1 receptor agonist; and Prof. Jae Hyun Bae will focus on CagriSema, a fixed-dose combination of cagrilintide and semaglutide. This session will highlight the clinical significance and therapeutic potential of next-generation agents for advancing the treatment of metabolic diseases.

This session explores the multifaceted origins of metabolic disorders by integrating genetic predispositions, epigenetic regulations, and environmental influences. Experts will discuss how polygenic risk scores define obesity endotypes, how epigenetic mechanisms in adipose tissue drive insulin resistance, and how the exposome interacts with lifestyle to shape metabolic health. By bridging the gap between innate susceptibility and external factors, this symposium provides a comprehensive framework for the future of precision medicine in endocrinology. This integrative approach offers vital insights into personalized strategies for the prevention and treatment of complex metabolic diseases.

This session covers the latest developments in connected devices that are changing the way we manage diabetes. First, we will look at how fully closed loop insulin delivery systems are being used in patients with type 2 diabetes, along with recent clinical evidence. Next, we will explore the use of smart insulin pens and their clinical benefits in type 1 diabetes and advanced type 2 diabetes requiring insulin therapy. We will also introduce current trends in continuous glucose monitoring (CGM) technology and how it continues to evolve. Through this session, attendees will gain a better understanding of where digital diabetes management stands today and where it is headed, as well as practical information that can be applied in everyday clinical practice.